MyanmarTuberculosis profile
Population  2015 54 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 27 (16–40) 49 (30–74)
Mortality (HIV+TB only) 4.8 (3.5–6.5) 9 (6.4–12)
Incidence  (includes HIV+TB) 197 (144–258) 365 (267–479)
Incidence (HIV+TB only) 17 (11–25) 32 (21–47)
Incidence (MDR/RR-TB)** 14 (8.9–18) 26 (17–33)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 6 (2.4–9.6) 66 (35–97) 72 (38–106)
Males 7.7 (4.8–11) 117 (87–147) 125 (92–158)
Total 14 (9.4–18) 183 (152–214) 197 (144–258)
TB case notifications, 2015  
Total cases notified 140 700
Total new and relapse 138 447
          - % tested with rapid diagnostics at time of diagnosis 22%
          - % with known HIV status 65%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 39%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 70% (54–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.16 (0.1–0.26)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 7 918 9%
          - on antiretroviral therapy 3 034 38%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  9 000
(6 400–12 000)
Estimated % of TB cases with MDR/RR-TB 5.1% (3.2–7) 27% (15–39)  
% notified tested for rifampicin resistance 7% 46% 14 599
MDR/RR-TB cases tested for resistance to second-line drugs   43
Laboratory-confirmed cases MDR/RR-TB: 2 793, XDR-TB: 11
Patients started on treatment **** MDR/RR-TB: 2 207, XDR-TB: 7
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 87% 135 984
Previously treated cases, excluding relapse, registered in 2014 73% 3 677
HIV-positive TB cases, all types, registered in 2014 70% 10 782
MDR/RR-TB cases started on second-line treatment in 2013 83% 667
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
3.6% (3.3–3.9)
TB financing, 2016  
National TB budget (US$ millions) 69
Funding source: 21% domestic, 52% international, 28% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-01-24 Data: www.who.int/tb/data